Venetoclax TDM Reduces Toxicity Risk in Posaconazole-Treated AML Patients
Oncology Pharmacy Hypothesis-generating Grade: Low
Sani B, Cignetti A, Leporati M, et al.
📅 Jul 25, 2026 · Oncology research
Venetoclax levels spike with posaconazole: TDM is essential.
Immunotherapy May Enable Safe Axillary De-escalation in Node-Positive TNBC
Oncology Pharmacy Hypothesis-generating Grade: Low
Li Z, Qu Z, Pei S, et al.
📅 Jul 23, 2026 · Frontiers in immunology
Chemo-immunotherapy may enable less invasive breast cancer surgeries.
Two-Year Lenalidomide Maintenance Matches Indefinite Therapy in Standard-Risk Myeloma
Oncology Pharmacy Practice-changing Grade: Moderate
Kumar S, Jacobus S, Cohen A, et al.
📅 Jul 16, 2026 · N Engl J Med
Two-year lenalidomide is as effective as indefinite therapy in multiple myeloma.
Adjuvant TACE and Lenvatinib-Tislelizumab Show Comparable Post-Resection Benefit
Oncology Pharmacy Hypothesis-generating Grade: Low
Feng X, Ao Y, Wang L, et al.
📅 Jul 14, 2026 · Frontiers in immunology
Adjuvant therapies improve survival in high-risk liver cancer patients.
Immune Checkpoint Inhibitors Redefine First-Line Cholangiocarcinoma Therapy
Oncology Pharmacy Confirmatory Grade: Moderate
Nisa FU, Ali M, Khan T, et al.
📅 Jul 6, 2026 · Journal of the Egyptian National Cancer Institute
Immune checkpoint inhibitors redefine advanced cholangiocarcinoma treatment.
Targeted Therapy Evolution: From Kinase Inhibitors to Protein Degraders
Oncology Pharmacy Hypothesis-generating Grade: Very Low
Wang Y, Tang SC
📅 Jun 27, 2026 · Critical reviews in oncology/hematology
Targeted cancer therapies revolutionize personalized oncology treatment.
EML4-ALK in NSCLC: Targeting Drug Resistance
Oncology Pharmacy
Li S, Bao L, Zhou D, et al.
📅 Jun 26, 2026 · Technology in cancer research & treatment
EML4-ALK fusion: A precision target in NSCLC fraught with resistance challenges.
Vitamin D3 Enhances Chemotherapy in Metastatic CRC
Oncology Pharmacy
Rahman AMA, Hassan NA, Hamza MS, et al.
📅 Jun 25, 2026 · Asian Pacific journal of cancer prevention : APJCP
Vitamin D3 boosts chemotherapy response in metastatic CRC.
Refining Timing: Immunotherapy in Resectable NSCLC
Oncology Pharmacy
Osarogiagbon RU, Cetnar JP, Aljumaily R
📅 Jun 23, 2026 · American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
New trials may refine lung cancer therapy timing strategies.
KDIGO Consensus Reframes Kidney-Heart Failure Comanagement Priorities
Oncology Pharmacy Confirmatory Grade: Low
Izzedine H, Perazella MA, Kuruvada KM, et al.
📅 Jun 20, 2026 · Kidney international
Preventing kidney damage in cancer treatment requires proactive strategies.
Venetoclax Combinations Redefine Chemotherapy-Free CLL Treatment Paradigms
Oncology Pharmacy Confirmatory Grade: Moderate
Kegyes D, Muresan X, Bancos A, et al.
📅 Jun 11, 2026 · Critical reviews in oncology/hematology
Venetoclax brings new promise to chronic lymphocytic leukemia management.
Adjuvant TACE and Lenvatinib-Tislelizumab Show Comparable Recurrence Benefit in HCC
Oncology Pharmacy Hypothesis-generating Grade: Low
Ministerial Meeting on Population of the Non-Aligned Movement (1993: Bali)
📅 Jun 1, 2026 · NEJM
This retrospective, propensity-matched comparison informs adjuvant regimen selection for resected high-risk hepatocellular carcinoma, weighing locoregional chemoembolization against a targeted-immunotherapy combination.
Biomarker Strategies for Chemotherapy Cardiotoxicity: Promise Versus Validation
Oncology Pharmacy Confirmatory Grade: Very Low
Kong Y, He R, He H, et al.
📅 Feb 25, 2026 · Rev Cardiovasc Med
New biomarkers offer promise for early detection of chemotherapy-induced heart damage.
Dual PD-L1/Galectin-9 CRISPR nanoparticles curb melanoma in mice
Oncology Pharmacy Hypothesis-generating Grade: Very Low
Fang T, Deng Y, Chen M, et al.
📅 Jun 6, 2025 · Biomaterials
CRISPR-loaded nanoparticles boost immune response against cancer.